Ibrutinib

SKU: orb1307353

特色

描述

Ibrutinib is a potent, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 0.5 nM. It suppresses B-cell proliferation and survival, demonstrating antitumor efficacy in both in vitro assays and in vivo models of B-cell malignancies like chronic lymphocytic leukemia.

研究领域

Immunology & Inflammation

图片与验证

−

关键属性

−

CAS 号	936563-96-1
MW	440.51
纯度	>98%
分子式	C₂₅H₂₄N₆O₂
SMILES	NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
靶点	Kinase
溶解性	Soluble in DMSO (up to at least 25 mg/ml)

生物活性

−

靶点 IC50	BTK:0.5 nM (cell free)\|Brk:3.3 nM (cell free)\|FGR:2.3 nM (cell free)\|BLK:0.5 nM (cell free)\|BMX kinase:0.8 nM (cell free)\|CSK:2.3 nM (cell free)
体内	PCI-32765 (3.125, 12.5, or 50 mg/kg per day) markedly inhibited clinical arthritis scores. Partial and nearly complete elimination of clinical signs of the disease occurred after 9 to 11 d of treatment at dosages of 3.125 and 12.5 mg/kg per day, respectively. An oral single dose of PCI-32765 at 3.125 mg/kg per day resulted in partial Btk occupancy in splenocytes, and the maximally efficacious dose (12.5 mg/kg per day) was sufficient to fully occupy Btk for 12 h . PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model (ED50: 2.6 mg/kg/day). PCI-32765 also prevented clinical arthritis in CAIA models. In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited .
体外	In DOHH2, a cell line in which the BCR pathway can be activated by stimulation with anti-IgG, Ibrutinib (PCI-32765) inhibits autophosphorylation of Btk (IC50: 11 nM), phosphorylation of Btk's physiological substrate PLCγ (IC50: 29 nM), and phosphorylation of a further downstream kinase, ERK (IC50: 13 nM). Continuous exposure to 10 nM PCI-32765 for 18 h completely prevented up-regulation of the B-cell activation marker CD69. A 1-h pulse exposure to 10 nM PCI-32765 resulted in a similar level of CD69 inhibition in B cells . PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50: 8 nM). Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 production in primary monocytes (IC50s: 2.6/0.5/3.9 nM). Following FcεRI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD(2), TNF-α, IL-8, and MCP-1 . Treatment of CD40 or BCR activated CLL cells with PCI-32765 results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-κB. In addition, PCI-32765 inhibits activation-induced proliferation of CLL cells in vitro and effectively blocks survival signals provided externally to CLL cells from the microenvironment .
细胞研究	CD20+ B and CD3+ T cells were purified by negative selection (RosetteSep, >90% purity) from buffy coat PBMCs and viably frozen in 10% DMSO. Cells were thawed at 37 °C and maintained in growth media (RPMI media containing 10% FCS). B cells were stimulated with goat anti-human IgM F(ab′)2 (10 μg/mL) and T cells were stimulated with anti-CD3/CD28 coated beads at a 1:1 bead/cell ratio. Cells were stained with PE-CD69 and analyzed by flow cytometry, gating on viable lymphocytes. PCI-32765 at concentrations lower than 10 μM did not decrease B- or T-cell viability during the course of the experiment, although PCI-32765 did block the modest survival benefit of anti-IgM stimulation in B cells. For washout experiments, cells were rinsed three times in 10 volumes of growth media, a protocol that was confirmed to completely wash away inhibition of BCR signaling by PCI-29732, a reversible Btk inhibitor .
动物研究	ale DBA/1 mice were immunized with type II collagen plus Freund adjuvant and boosted 21 d later. On a rolling basis, as significant swelling appeared in at least one paw, mice were enrolled and randomized. PCI-32765 or dexamethasone (0.2 mg/kg) was administered orally once per day for 11 d. Arthritis scores (0–5) were assigned to the mice based on the degree and extent of paw swelling. Mouse anti-type II collagen antibody and total IgG levels were measured by ELISA. Female MRL/MpJ-Faslpr mice received PCI-32765 by oral gavage once per day from week 8 through week 20. Proteinuria was monitored weekly. At week 20, serum was collected and analyzed for BUN and mouse anti-dsDNA antibody levels. Kidney histology was scored according to established criteria (26). No drug-induced weight loss was observed at any of the dose levels tested. These studies were carried out at Boulder Biopath according to approved animal care protocols. Results are presented as the mean ± SEM. Statistical significance between groups were evaluated with repeated measures one-way ANOVA or one-way ANOVA using GraphPad Prism with Tukey or Bonferroni multicomparison posttest .

储存与操作

−

储存	-20°C
有效期	12 months from date of receipt.
免责声明	For research use only

别名

−

PCI-32765

相似产品

−

SRX3305 [orb1785911]
纯度：
>97%
CAS 号：
2409965-28-0
MW:
424.471
分子式：
C₂₂H₂₀N₂O₅S
可选规格： 5 mg
Ironomycin [orb3174198]
CAS 号：
1884647-72-6
MW:
788.08
分子式：
C₄₅H₇₃NO₁₀
可选规格： 10 mg, 50 mg
Ibrutinib impurity 14 [orb3181568]
CAS 号：
2031255-26-0
MW:
472.55
分子式：
C₂₆H₂₈N₆O₃
可选规格： 10 mg, 50 mg
Ibrutinib impurity 28 [orb3181481]
CAS 号：
2213398-75-3
MW:
317.35
分子式：
C₁₈H₁₅N₅O
可选规格： 10 mg, 50 mg
Ibrutinib impurity 23 [orb3181394]
CAS 号：
1917333-91-5
MW:
494.56
分子式：
C₂₈H₂₆N₆O₃
可选规格： 50 mg, 10 mg

质量保证

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our 条款与条件和选购指南.

化合物标识

PubChem CID

24821094 ↗

关键属性

−

暂无计算属性。

实验方案信息

查看更多实验方案

纯度：	>97%
CAS 号：	2409965-28-0
MW:	424.471
分子式：	C₂₂H₂₀N₂O₅S

CAS 号：	1884647-72-6
MW:	788.08
分子式：	C₄₅H₇₃NO₁₀

CAS 号：	2031255-26-0
MW:	472.55
分子式：	C₂₆H₂₈N₆O₃

CAS 号：	2213398-75-3
MW:	317.35
分子式：	C₁₈H₁₅N₅O

CAS 号：	1917333-91-5
MW:	494.56
分子式：	C₂₈H₂₆N₆O₃

Ibrutinib

描述

研究领域

图片与验证

关键属性

生物活性

储存与操作

别名

相似产品

SRX3305 [orb1785911]

Ironomycin [orb3174198]

Ibrutinib impurity 14 [orb3181568]

Ibrutinib impurity 28 [orb3181481]

Ibrutinib impurity 23 [orb3181394]

质量保证

化合物标识

关键属性

实验方案信息

可选规格